A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
5actual
Sites
51
Countries
Australia, France, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-13 | actual | When the study began enrolling |
| Primary completion | 2025-12-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-03 | actual | The whole study's end, after follow-up |
| First posted | 2022-02-24 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-26 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma, Non-Hodgkin
- Hodgkin Disease
Interventions
- Drug: Relatlimab — also filed as BMS-986016
- Drug: Nivolumab — also filed as BMS-936558
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Dose-Limiting Toxicities (DLTs) - Part A
measured 1 cycle, defined as 28 days
Complete Metabolic Response (CMR) Rate - Part B
measured From first dose until the first documented response
Number of Participants With Adverse Events (AEs) - Part A
measured From first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants Who Died - Part A
measured from first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Serious Adverse Events (SAEs) - Part A
measured from first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Adverse Events (AEs) Leading to Discontinuation - Part A
measured From first dose to 135 days post last dose (Up to approximately 11 months)
Number of Participants With Laboratory Abnormalities - Part A
measured From first dose to 30 days post last dose (Up to approximately 8 months)
Maximum Serum Concentration (Cmax)
measured Cycle 1 Day 1
Time to Maximum Concentration (Tmax)
measured Cycle 1 Day 1
Area Under the Concentration-time Curve [AUC(TAU)]
measured Cycle 1 Day 1
Concentration Trough (Ctrough)
measured Cycle 2 Day 1, Cycle 4 Day 1, Cycle 6 Day 1
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2024-08-19 · 28.8 MB · Prot_SAP_000.pdf
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed